Australians Immunised With AstraZeneca Vaccine May Face Potential EU Travel Restrictions
July 22, 2021
Aussie travellers hoping to visit European destinations this summer may face potential restrictions since the vaccine manufactured in Australia still needs to be approved by the European Union and the European Medicines Agency (EMA).
Even though the Aussie-made COVID-19 vaccine is entirely the same as the ones being manufactured in the Netherlands, Belgium, or the UK, technically speaking, the vaccine has not been authorised yet since the Melbourne facility of the Commonwealth Serum Laboratories (CSL) hasn’t registered with the EU drug regulator, SchengenVisaInfo.com reports.
In contrast, facilities manufacturing the AstraZeneca vaccine in the United States, South Korea, and China have all been registered to the drug regulator, meaning they are widely recognised.
2 five-star stocks to buy fool.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com.au Daily Mail and Mail on Sunday newspapers.
‘First time in history’: RBA’s first gender-balanced board By Sarah Buckley 30 December 2020
Two more women have been appointed to the RBA’s board, making it “gender-balanced for the first time in history”, according to Treasurer Josh Frydenberg.
The Morrison government has appointed Coca-Cola Amatil group managing director Alison Watkins and Commonwealth Serum Laboratories (CSL) director Carolyn Hewson as members of the Reserve Bank Board, each for a five-year period.
Ms Hewson and Ms Watkins replace Allan Moss, previous director of Macquarie Group, and Catherine Tanna, managing director of EnergyAustralia.
Ms Watkins’ experience comprises senior roles in agriculture and banking sectors. As well as being the group managing director of Coca-Cola Amatil, she is also a Business Cou
H1N1 Vaccine Market Size Forecast to Reach $2.3 Billion by 2025 Increasing Incidences of Epidemic H1N1 Infection and Declining Immunity Among the Geriatric Population Is Increasing the Growth of the H1N1 Vaccine Market.
BriefingWire.com, 12/21/2020 - H1N1 Vaccine Market size is forecast to reach $2.3 billion by 2025, growing at a CAGR of 4.51% during the forecast period 2020-2025. H1N1 influenza virus or swine H1N1 virus is a causative agent of infectious disease caused in human beings known as H1N1 or commonly referred to as swine flu. The H1N1 virus mainly affects the respiratory system including the nose, lungs, and throat of the infected person. Increasing incidences of epidemic H1N1 infection and declining immunity among the geriatric population are the major factors driving the growth of the market.
No homegrown coronavirus vaccine, but CSL inoculated against failure
Posted
FriFriday 11
updated
FriFriday 11
CSL was founded in 1916 as Commonwealth Serum Laboratories.
(
Print text only
Cancel
Australia won t save the world, this time, after trials of our promising COVID vaccine were abandoned.
Key points:
This year it briefly had the largest market capitalisation on the ASX
Blood products and vaccines powered a $2 billion profit this year
It s a rare setback for biotech behemoth CSL.
CSL is one of our largest companies a global biotech giant worth more than some of our biggest banks but one that many Australians would have never heard of.